Earlier this month at the J.P. Morgan Healthcare Conference, Regeneron got its Eylea sales news out of the way. | For the ...

Sun Pharma's board also approved an interim dividend of ₹11 per equity share of ₹1 each of the firm for the financial year ...

The India formulations business clocked sales of Rs 4,998.6 crore, registering a growth of 16.2 per cent. The domestic market ...

Sun Pharmaceutical Industries Ltd on Friday reported its consolidated financial results for the third quarter ended December ...

Sanofi’s vaccine sales dipped 2.5% in 2025, with almost all immunization products declining. Nevertheless, CEO Paul Hudson ...

On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly ...

While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026. | While the threat of U.S. import tariffs ...

Sun Pharma beat Q3 estimates with a consolidated net profit of ₹3,369 crore, driven by steady domestic growth and innovative drug sales offsetting the decline in generic sales in the US.

Reported Standalone quarterly numbers for Balaxi Pharmaceuticals are: Net Sales at Rs 24.59 crore in December 2025 up 120.41% ...